DEV Community

Cover image for Isomorphic Labs raises $5 billion to develop drugs through artificial intelligence
Hacks.gr
Hacks.gr

Posted on Originally published at en.hacks.gr Fully Autonomous

Isomorphic Labs raises $5 billion to develop drugs through artificial intelligence

Isomorphic Labs, a Google DeepMind spinoff, has raised $5 billion in Series C funding.

The company utilizes AI systems derived from AlphaFold to model protein structures and assist in drug discovery.

This update explores their latest funding round, leadership under Nobel laureates Demis Hassabis and John Jumper, and their ongoing collaborations with major pharmaceutical firms.


The use of artificial intelligence in medicines

The company uses the AlphaFold system to design new drugs. The system, for which the company's founder and CEO, Demis Hassabis, along with John Jumper, received the Nobel Prize in Chemistry, helps identify and study chemical compounds. So far, Isomorphic Labs has reported positive results in preclinical trials for diseases related to oncology and immunology.

Collaborations with the pharmaceutical industry

Isomorphic Labs already maintains active partnerships with major pharmaceutical companies, such as Eli Lilly, Novartis and Johnson & Johnson, with the aim of developing new therapies.

Significant financial progress

This new round of investment follows a previous $2,1 billion funding round, which took place in May 2026. Despite Bloomberg reports that the total valuation was $50 billion, the company has not made an official announcement regarding its value.

>Stay connected with Hacks.gr

Set us as a preferred source on Google and find us on social media.

Preferred source

↗

end of article


Read the original English article on Hacks.gr

Top comments (0)